IPOs Numbers Rise In 2024 But Dwindling Returns Could Diminish Potential In 2025
New Year Still Off To Good Start With Five Offerings
Most biopharma firms that went public in the US in 2024 had a strong start, but by year-end many were trading in negative territory and in 2025 most are below their IPO values, raising questions about IPO prospects in 2025.
